Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NCT06422143 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

851

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer
NSCLC

Interventions

BIOLOGICAL: Pembrolizumab
BIOLOGICAL: sac-TMT
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Nab-paclitaxel

Sponsor

Merck Sharp & Dohme LLC